Indication
Folic acid deficient megaloblastic anemia
Folic acid deficient megaloblastic anemia is a hematologic disorder caused by insufficient folate levels, which disrupts purine and thymidylate synthesis necessary for normal DNA replication in rapidly dividing hematopoietic precursors. Read more about Folic acid deficient megaloblastic anemia
62 drugs 60 manufacturers
Drugs that treat it
Common Folic acid deficient megaloblastic anemia therapies.
LEUCOVORIN CALCIUM
FOLIC ACID
VYKOURA (leucovorin calcium)
QUIOFIC (folic acid)
FOLIC ACID
FOLIC ACID
LEUCOVORIN CALCIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonFolic acid deficient megaloblastic anemia is a hematologic disorder caused by insufficient folate levels, which disrupts purine and thymidylate synthesis necessary for normal DNA replication in rapidly dividing hematopoietic precursors.
It primarily impacts the bone marrow and circulating red blood cells across diverse patient populations, particularly individuals with inadequate dietary intake, intestinal malabsorption, alcoholism, or increased physiological demands such as pregnancy or chronic hemolysis.
Clinically and pathophysiologically, the condition is defined by impaired nuclear maturation alongside normal cytoplasmic development (nuclear-cytoplasmic dyssynchrony), resulting in enlarged erythroblasts (megaloblasts), macrocytic red blood cells, hypersegmented neutrophils, and ineffective erythropoiesis leading to fatigue, pallor, and weakness.
- nih.gov
Folic acid deficient megaloblastic anemia is a hematologic disorder caused by insufficient folate levels, which disrupts purine and thymidylate synthesis necessary for normal DNA replication in rapidly dividing hematopoietic precursors It primarily impacts the bone marrow and circulating red blood cells across diverse patient populations, particularly individuals with inadequate dietary intake, intestinal malabsorption, alcoholism, or increased physiological demands such as pregnancy or chronic ...
- nih.gov
Folic acid deficient megaloblastic anemia is a hematologic disorder caused by insufficient folate levels, which disrupts purine and thymidylate synthesis necessary for normal DNA replication in rapidly dividing hematopoietic precursors
- ccjm.org
It primarily impacts the bone marrow and circulating red blood cells across diverse patient populations, particularly individuals with inadequate dietary intake, intestinal malabsorption, alcoholism, or increased physiological demands such as pregnancy or chronic hemolysis
- medlineplus.gov
Clinically and pathophysiologically, the condition is defined by impaired nuclear maturation alongside normal cytoplasmic development (nuclear-cytoplasmic dyssynchrony), resulting in enlarged erythroblasts (megaloblasts), macrocytic red blood cells, hypersegmented neutrophils, and ineffective erythropoiesis leading to fatigue, pallor, and weakness
- childrenshospital.org
Clinically and pathophysiologically, the condition is defined by impaired nuclear maturation alongside normal cytoplasmic development (nuclear-cytoplasmic dyssynchrony), resulting in enlarged erythroblasts (megaloblasts), macrocytic red blood cells, hypersegmented neutrophils, and ineffective erythropoiesis leading to fatigue, pallor, and weakness
Personalize your experience
Follow Folic acid deficient megaloblastic anemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.